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tivariate sensitivity analysis of avoided costs was carried out. All results are presented 
annualized and costs expressed in c2009. RESULTS: A total of 1365 patients were 
included, 79.5% males, mean (±SD) age was 71.4 (±10,3), mean FEV1 was 65.34% 
and a COPD history of 5.5 (±2,9) years. Patients were divided into GOLD group and 
NO-GOLD group and in stage II (FEV1 < 80% and ≥50%) and stage III (FEV1 < 50% 
and ≥30%) for both groups. Total annual costs per patient were analyzed. Directs 
costs analyzed were treatment, medical visits, emergency visits, hospital stay, labora-
tory, spirometry, radiology and oxigenotherapy. Indirect cost evaluated was sick leave. 
Avoided costs between both groups will be analyzed, and conﬁ rmed with sensitivity 
analysis. CONCLUSIONS: The results of this study will provide whether the adher-
ence to the recommendations of the GOLD guidelines in COPD patients can lead to 
signiﬁ cant savings to the Spanish health care system.
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OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications including longer length of hospital stay and resulting treatment costs. 
a PEG hydrogel sealant (PleuraSeal™) is used as an adjunct to standard closure of 
pleural air leaks during lung resection surgery and has demonstrated shorter hospital-
izations (1.7 fewer days; Wain JC et al, 2008, Conference Abstract) and more rapid 
removal of chest tubes in a clinical study (Covidien, data on ﬁ le) when compared with 
standard closure (e.g. staples and sutures alone). Our study was designed to estimate 
the potential cost offsets for using PleuraSeal™ compared with standard closure in 
100 hypothetical patients from a Spanish hospital who had an air leak after lung 
resection surgery using the cost offset from shorter hospital stays balanced against the 
cost for PleuraSeal™. METHODS: We assumed the cost for PleuraSeal™ in Spain to 
be c420 per treatment applied to all 100 hypothetical patients compared with no 
added cost for standard closure. We then balanced the added cost for PleuraSeal™ 
with the reduction in number of hospital days and subsequent costs (c590/day [Varela 
et al, 2006] @1.7 fewer days per patient) compared with standard closure and calcu-
lated the potential cost offset for PleuraSeal™. RESULTS: A Spanish hospital that 
performs 100 lung resections with air leaks can expect to save c58,300, or approxi-
mately c583 per patient when compared to standard closure as patients who had air 
leaks stayed in hospital an average of 1.7 days longer than those without air leaks. 
CONCLUSIONS: The cost for PleuraSeal™ is completely offset by the shorter length 
of hospital stay compared with standard closure inSpain. PleuraSeal™ is a compelling 
option for Spanish hospitals that perform lung resection surgeries as the cost of the 
treatment is completely offset by the reduction in air leaks and subsequent shorter 
hospital stay.
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OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications. a PEG hydrogel sealant (PleuraSeal™) is used as an adjunct to standard 
closure of pleural air leaks and has demonstrated shorter hospitalizations (1.7 fewer 
days; Wain JC et al, 2008, Conference Abstract) when compared with standard of 
care (e.g. staples and sutures alone). Our study was designed to estimate the potential 
cost offsets for using PleuraSeal™ in 100 hypothetical patients with an air leak using 
the cost offset from shorter hospital stays balanced against the cost for PleuraSeal™. 
METHODS: We assumed the cost for PleuraSeal™ in Italy to be c420 per treatment 
applied to all 100 hypothetical patients compared with no added cost for standard of 
care. We then balanced the cost for PleuraSeal™ with the reduction in hospital days 
and subsequent costs (c337/ thoracic ward day, a Brunelli et al, 2007), then calculated 
the potential cost offset for PleuraSeal™. RESULTS: An Italian hospital that performs 
100 lung resections with air leaks can expect to save c15,300, or approximately c153 
per patient when compared to standard of care as patients who had air leaks stayed 
in hospital an average of 1.7 days longer than those without air leaks. CONCLU-
SIONS: The cost for PleuraSeal™ is completely offset by the shorter length of hospital 
stay compared with standard of care in Italy. PleuraSeal™ is a compelling option for 
Italian hospitals that perform lung resection surgeries as the cost of the treatment is 
completely offset by the reduction in air leaks and subsequent shorter hospital stay.
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OBJECTIVES: Therapeutic reference pricing (TRP) is one of the most frequently 
employed methods for cost-containment of pharmaceuticals. The Hungarian National 
Health Insurance Fund (NHIF) applies TRP based on DDD, yet even the WHO objects 
to using DDD in pricing and reimbursement decisions. Our objective was to compare 
actual drug use to DDD and to evaluate whether TRP based on DDD could result in 
savings in the costs of maintenance medication and the total direct health expenditures 
between asthma patients treated with Symbicort Turbuhaler (SYT) and Seretide Diskus 
(SED). METHODS: Real world data for the analysis was derived from the NHIF 
database. Actual drug use and average costs were compared in four groups (high dose 
SYT, medium dose SYT, high dose SED and medium dose SED). Multiple linear 
regression was employed to adjust data for the differences in gender and age distribu-
tion of patients. RESULTS: A total of 12,260 patients using SED and 15,539 patients 
using SYT for asthma were involved into the analysis. Average drug use was lower in 
both groups than DDD. Patients used 1.38–1.95 inhalations in both SED groups, 
1.28–1.97 inhalations in the high dose SYT group, and 1.74–2.49 inhalations in the 
medium dose SYT group. Although the daily therapeutic cost of medium dose SED 
based on DDD would be much lower than the cost of SYT, no difference was found 
in the actual cost of the maintenance therapy or the total medical costs. CONCLU-
SIONS: Our analysis provides evidence about the limitation of employing daily 
therapy costs according to DDD for TRP. No relationship was found between the 
daily therapeutic costs calculated using the NHIF methodology and costs of real drug 
use, in real world TRP did not lead to the reduction of expenditures from the payer’ 
perspective. Potential confounding factors may limit the generalizability of 
conclusions.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) currently represents 
the ﬁ fth leading cause of death worldwide and it’s estimated to rise to the third cause 
by 2030. Few studies have estimated the burden of COPD. The aim of this study was 
to evaluate consumption and cost of health care resources of severe COPD patients 
in the general population from the Italian health care system perspective. METHODS: 
Data were extracted from Healthcare Administrative Databases (HADs) of the region 
of Lombardy, which covers a population of 9.2 million members. HADs related to 
eligibility criteria, hospital admissions, pharmaceutical and outpatient claims have 
been organized in a data warehouse using probabilistic record linkage. The study 
included subjects aged more than 18 years that in 2003 had at least one hospitalization 
with COPD as the main diagnosis or as the second one when the main was: pneumo-
nia, respiratory or heart failure, pneumothorax and acute pulmonary heart disease. 
Subjects were followed for two years collecting information on health care resource 
and vital status. Severe and moderate exacerbations of COPD were respectively 
deﬁ ned as hospitalizations for COPD and as prescriptions of corticosteroids and/or 
antibiotics after the index hospitalization. RESULTS: We selected 16,476 patients 
with age mean 76 years and an average follow-up of 19 months. The 38% of patients 
were women with mean age three years higher than men. Subjects with severe exac-
erbations had on average 4.4 moderate and 1.9 severe episodes after the index hospi-
talization. The mean annual cost for these patients was c11,824 (IC95% 
11,554–12,079). Patients with only moderate exacerbations had on average 3.9 mod-
erate exacerbations and the mean annual cost was c6413 (IC95% 6288–6549). Costs 
were steady in time. CONCLUSIONS: The burden of COPD is important both in 
frequency and cost; it requires an effort in programming new health services particu-
larly devoted to aging population.
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OBJECTIVES: This analysis estimates the health care costs (hospitalizations and 
outpatient visits) due to respiratory and co-morbid diseases in a cohort of subjects 
with and without COPD in Sweden. METHODS: A cohort of individuals was identi-
ﬁ ed in earlier clinical examinations of the general population within the Obstructive 
Lung Disease in Northern Sweden (OLIN) Studies. The cohort consisted initially of 
993 subjects fulﬁ lling criteria (GOLD) for COPD and an age- and gender matched 
control group of same size without obstructive lung function impairment. Since 2005, 
these subjects have been invited to yearly interviews and examinations. The participa-
tion rate has been high, above 85%. This analysis is based on resource use data col-
lected in 2006 (n = 772 COPD, n = 802 non-COPD). Unit costs from the Northern 
health care region price list of 2010 were used. RESULTS: The mean health care costs 
of all diseases amounted to c1421 (median c236) annually per subject with COPD 
compared to c1127 (median c169) for subjects without COPD (p = 0.16, non-
parametric Mann-Whitney). The mean costs in relation to disease severity were 
(GOLD criteria severity stage; p-value COPD vs. non-COPD): c1166 (mild; p = 0.66), 
c1755 (moderate; p = 0.28), c2223 (severe+very severe; P < 0.01). a minor part of the 
costs was attributable to respiratory diseases; 5.8% in non-COPD subjects and 10.5% 
in subjects with COPD. Respiratory disease costs were statistically signiﬁ cantly higher 
among subjects with COPD in all disease severity stages. CONCLUSIONS: The mean 
annual health care costs were c294 (median c67) higher for subjects with COPD. The 
difference in costs between subjects with severe+very severe COPD and subjects 
without the disease was statistically signiﬁ cant.
